Neeraj Y. Saini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neeraj Y. Saini has a total of 416 co-authors. Here are the top co-authors by number of shared publications:
- Michael D. Jain
Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL, USA
40 shared publications - Marco L. Davila
Roswell Park Comprehensive Cancer Center
39 shared publications - Frederick L. Locke
Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida
38 shared publications - Johannes Francois Fahrmann
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
33 shared publications - Aleksandr Lazaryan
Moffitt Cancer Center, Tampa, Florida, United States
32 shared publications - Bijal D. Shah
Moffitt Cancer Center, Tampa, USA
32 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
A novel KIR3DL2-directed CAR T-cell therapy for cutaneous and systemic T-cell lymphomas
From the 2026 National Summit on Hematologic Cancers
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessA novel KIR3DL2-directed CAR T-cell therapy for cutaneous and systemic T-cell lymphomas
From the 2026 National Summit on Hematologic Cancers
- Open Access
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
A Novel CD94-targeting CAR T Cell Therapy for Cytotoxic Subtypes of T/NK-cell Malignancies
From the 2026 National Summit on Hematologic Cancers
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessA Novel CD94-targeting CAR T Cell Therapy for Cytotoxic Subtypes of T/NK-cell Malignancies
From the 2026 National Summit on Hematologic Cancers
- Open Access
- 24 September 2026
- Published by Elsevier in SSRN Electronic Journal
A case report of extramedullary plasmacytoma presenting as a large pelvic mass
- 24 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA case report of extramedullary plasmacytoma presenting as a large pelvic mass
- Open Access
Microbial valerate is associated with CAR T dysbiosis and its supplementation enhances CAR T function in B-cell lymphoma
Anaerobe-depleting antibiotic exposure is associated with inferior progression-free survival after CD19 CAR T-cell therapy in large B-cell lymphoma, yet the cellular mechanisms linking gut dysbiosis to the CAR T-cell product and whether this imprint is reversible have remained undefined. In two independent CAR-T candidate cohorts, low stool valerate at the time of CAR-T eligibility identified a multi-metabolite-deficient dysbiotic gut microbiome state marked by depletion of fiber-fermenting commensals and loss of carbohydrate-fermentation, SCFA-biosynthesis, and amino-acid metabolism pathways. Reanalysis of single-cell RNA sequencing from 42 lymphoma patients stratified by piperacillin-tazobactam/imipenem/meropenem (PIM) exposure revealed that PIM-exposed CAR T-cell products were CD4-skewed, with significantly elevated AP-1/immediate-early gene (IEG) and cellular activation signatures that together predicted inferior progression-free survival. Ex vivo conditioning of CAR T-cells with valerate produced a chromatin and transcription factor program distinct from butyrate or propionate, characterized by KLF/SP/EGR family engagement, KLF4 promoter opening, and broad induction of AP-1/IEG and MHC class II transcripts, whereas butyrate drove broader chromatin remodeling with TBX21/EOMES/NF-κB gains and KLF2 promoter closure, and propionate induced an NFY-centered program with preferential commitment to low-mitochondrial-content states. Untargeted metabolomics confirmed valerate uptake and mitochondrial β-oxidation in CAR T-cells, while dietary sodium valerate supplementation in meropenem-treated mice bearing A20 lymphoma significantly reduced tumor burden and extended survival compared with CAR T-cells alone. These findings identify stool valerate as a bedside-deployable biomarker of dysbiosis-imprinted CAR T-cell dysfunction and support ex vivo or dietary valerate supplementation as a clinically tractable strategy to improve CAR-T anti-tumor function in patients with disrupted gut microbiomes.
Open AccessMicrobial valerate is associated with CAR T dysbiosis and its supplementation enhances CAR T function in B-cell lymphoma
Anaerobe-depleting antibiotic exposure is associated with inferior progression-free survival after CD19 CAR T-cell therapy in large B-cell lymphoma, yet the cellular mechanisms linking gut dysbiosis to the CAR T-cell product and whether this imprint is reversible have remained undefined. In two independent CAR-T candidate cohorts, low stool valerate at the time of CAR-T eligibility identified a multi-metabolite-deficient dysbiotic gut microbiome state marked by depletion of fiber-fermenting commensals and loss of carbohydrate-fermentation, SCFA-biosynthesis, and amino-acid metabolism pathways. Reanalysis of single-cell RNA sequencing from 42 lymphoma patients stratified by piperacillin-tazobactam/imipenem/meropenem (PIM) exposure revealed that PIM-exposed CAR T-cell products were CD4-skewed, with significantly elevated AP-1/immediate-early gene (IEG) and cellular activation signatures that together predicted inferior progression-free survival. Ex vivo conditioning of CAR T-cells with valerate produced a chromatin and transcription factor program distinct from butyrate or propionate, characterized by KLF/SP/EGR family engagement, KLF4 promoter opening, and broad induction of AP-1/IEG and MHC class II transcripts, whereas butyrate drove broader chromatin remodeling with TBX21/EOMES/NF-κB gains and KLF2 promoter closure, and propionate induced an NFY-centered program with preferential commitment to low-mitochondrial-content states. Untargeted metabolomics confirmed valerate uptake and mitochondrial β-oxidation in CAR T-cells, while dietary sodium valerate supplementation in meropenem-treated mice bearing A20 lymphoma significantly reduced tumor burden and extended survival compared with CAR T-cells alone. These findings identify stool valerate as a bedside-deployable biomarker of dysbiosis-imprinted CAR T-cell dysfunction and support ex vivo or dietary valerate supplementation as a clinically tractable strategy to improve CAR-T anti-tumor function in patients with disrupted gut microbiomes.
- Open Access
- 10 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3429-3440
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel
Increasing evidence suggests that the gut microbiome may influence the responses and toxicities associated with chimeric antigen receptor T-cell (CAR-T) therapy. We conducted whole-genome shotgun sequencing on stool samples (N = 117) collected at various times from patients with multiple myeloma (n = 33) who underwent idecabtagene vicleucel (ide-cel) anti–B-cell maturation antigen CAR-T therapy. We observed a significant decrease in bacterial diversity after ide-cel infusion, along with significant differences in the bacterial composition linked to therapy response and toxicities. Specifically, we found significant enrichment of Flavonifractor plautii, Bacteroides thetaiotaomicron, Blautia fecis, and Dysosmobacter species in ide-cel responders. A notable finding was the link of major microbiome disruption, defined as the presence of dominant specific taxa (>35% prevalence), and increased facultative pathobionts, like Enterococcus, with ide-cel toxicities, especially cytokine release syndrome (CRS). Patients with genus dominance in baseline samples had a higher incidence of grade 2 or higher CRS at 46.2% than those without genus dominance (11.1%; P = .043). In addition, network analysis and mass spectrometric assessment of stool metabolites revealed important associations and pathways, such as F plautii being linked to increased indole metabolites and pathways in responders. Our findings uncovered novel microbiome associations between ide-cel responses and toxicities that may be useful for developing modalities to improve CAR-T outcomes.
- 10 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3429-3440
Open AccessLongitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel
Increasing evidence suggests that the gut microbiome may influence the responses and toxicities associated with chimeric antigen receptor T-cell (CAR-T) therapy. We conducted whole-genome shotgun sequencing on stool samples (N = 117) collected at various times from patients with multiple myeloma (n = 33) who underwent idecabtagene vicleucel (ide-cel) anti–B-cell maturation antigen CAR-T therapy. We observed a significant decrease in bacterial diversity after ide-cel infusion, along with significant differences in the bacterial composition linked to therapy response and toxicities. Specifically, we found significant enrichment of Flavonifractor plautii, Bacteroides thetaiotaomicron, Blautia fecis, and Dysosmobacter species in ide-cel responders. A notable finding was the link of major microbiome disruption, defined as the presence of dominant specific taxa (>35% prevalence), and increased facultative pathobionts, like Enterococcus, with ide-cel toxicities, especially cytokine release syndrome (CRS). Patients with genus dominance in baseline samples had a higher incidence of grade 2 or higher CRS at 46.2% than those without genus dominance (11.1%; P = .043). In addition, network analysis and mass spectrometric assessment of stool metabolites revealed important associations and pathways, such as F plautii being linked to increased indole metabolites and pathways in responders. Our findings uncovered novel microbiome associations between ide-cel responses and toxicities that may be useful for developing modalities to improve CAR-T outcomes.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S2: Multivariable Cox fits with HR and 95% CI for NRM.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S2: Multivariable Cox fits with HR and 95% CI for NRM.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S2: Survival and Cumulative Incidence Analysis by Baseline SMI Depletion Categories.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure S2: Survival and Cumulative Incidence Analysis by Baseline SMI Depletion Categories.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S6: Association of corticosteroids and SMI loss.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S6: Association of corticosteroids and SMI loss.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 5: Baseline Serum Metabolomic Profiles Associated with Progression and Mortality.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Figure 5: Baseline Serum Metabolomic Profiles Associated with Progression and Mortality.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S5: Summary of clinical variables by SMI loss at day 90.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Supplementary Table S5: Summary of clinical variables by SMI loss at day 90.